(The order is not ranked)

Advaccine is an innovative vaccine and biopharmaceutical company with a product pipeline that includes novel vaccines and drugs targeting diseases caused by SARS-CoV-2, respiratory syncytial virus (RSV), and hepatitis B virus (HBV)—all of which are diseases with significant unmet medical needs. Among these, the RSV vaccine has shown leading clinical progress, with its product ADV110 demonstrating good safety and tolerability, and it has advanced to Phase II clinical trials.

CSPC Pharmaceutical Group has established a diversified product system, focusing on three major sectors: finished drugs, active pharmaceutical ingredients, and functional foods. The group has also actively contributed to the prevention and treatment of the coronavirus, with its mRNA COVID-19 vaccine being the first self-developed Chinese vaccine to receive emergency use authorization in China. In areas such as cardiovascular and cerebrovascular diseases and anti-tumor treatments, CSPC has launched products including Enbipu, Mingfule, Duo'enyi, and Jili Tai.Haiyitan, Duoen Da, Ouyue Xin and other innovative drugs. Its mRNA·RSV vaccine has already been submitted for clinical trials.

Watson Group is committed to the research and development of innovative vaccines and has established four major technology platforms: bacterial polysaccharide-protein conjugate vaccines, recombinant protein vaccines, mRNA vaccines, and recombinant adenovirus vector vaccines. To date, it has launched eight vaccine products and holds a leading position in the biotech pharmaceutical细分领域 of novel vaccines. The respiratory syncytial virus mRNA vaccine co-developed with Bluebird Biotechnology is currently in the preclinical research stage.

Amoy Vaccine has 8 commercialized vaccines targeting 6 disease areas, with 23 heavy-weight products under development, covering 14 disease fields. A total of 9 products have obtained 14 clinical approvals, among which 5 major products have entered Phase III clinical trials, and 9 are in the clinical stage. The products currently in production and under research cover all the top ten vaccine products ranked globally.

Zhifei Biological is a full-industry-chain biotech enterprise that integrates the research and development, production, sales, promotion, distribution, and import and export of vaccines and biological products. It collaborates with GSK China on GSK's Shingrix.^®Deepen cooperation and also reach a preliminary cooperation intention on the RSV vaccine developed and produced by GSK.

Sirnaomics is the world's first leading RNA therapeutics company to achieve positive Phase II clinical data in the oncology field. Its subsidiary, Arbutus Biopharma, has received approval from the U.S. Food and Drug Administration (FDA) for the Investigational New Drug (IND) application of its innovative mRNA vaccine RV-1770 targeting human RSV, and plans to initiate a Phase I clinical trial.

Clover Biopharmaceuticals is a global biopharmaceutical company at the commercial stage. Its technology platform, Trimer-Tag, is currently the world's only trimerization technology platform that uses human trimerization tags to produce recombinant covalently trimerized fusion proteins (trimer-tagged proteins). Relying on this platform, the Phase I clinical trial of the RSV candidate vaccine has now been initiated.

Kangtai Bio has the R&D and production capabilities for viral vaccines, bacterial vaccines, genetically engineered vaccines, conjugate vaccines, and multivalent combination vaccines. It has six products that have been marketed or obtained drug registration certificates. Additionally, it has initiated the development of a quadrivalent inactivated hand-foot-mouth disease vaccine, a 20-valent pneumococcal polysaccharide conjugate vaccine, and a recombinant respiratory syncytial virus vaccine (RSV), among others.

The RSV vaccine developed by Bowo Bio is a viral vector vaccine that uses replication-defective adenovirus type 5 (Ad5) as a vector, with the F protein, which induces the fusion of the RSV envelope with host cells, as the primary target of the RSV vaccine. This approach avoids the risk of "reversion to virulence" associated with live attenuated vaccines and the disease enhancement effect seen with inactivated vaccines.

The RSV vaccine developed by Bowo Biotech is a viral vector vaccine that uses replication-defective adenovirus type 5 (Ad5) as a vector, with the F protein, which induces the fusion of the RSV envelope with host cells, as the primary target of the RSV vaccine. This approach avoids the risk of "reversion to virulence" associated with live attenuated vaccines and the disease enhancement effect linked to inactivated vaccines.

Jia Chen Xi Hai has currently established a complete set of RNA synthesis, purification, and analytical quality control processes suitable for commercial production. It has also developed more efficient universal RNA templates (including self-replicating and non-self-replicating RNA). The pipeline covers tumor immunotherapy, infectious disease vaccines, rare diseases, and medical aesthetics. The company’s tumor immunotherapy and infectious disease vaccine projects are rapidly moving into the clinical trial stage.

Global vaccine products are scarce, with limited varieties, and the market is currently dominated by a duopoly, leaving a blue ocean market yet to be tapped.The development of RSV vaccines has been slow, with only two products currently on the market: GSK China's Arexvy and Pfizer’s Abrysvo, creating a temporary duopoly. In May 2023, the U.S. FDA approved GSK China's RSV vaccine Arexvy, followed by the approval of Pfizer's bivalent RSV vaccine Abrysvo in June of the same year. The approval of these two vaccines drove a rapid increase in sales for both GSK China and Pfizer, according to their Q3 2023 financial reports.Pfizer's Abrysvo sales reached $375 million, while GSK's Arexvy sales reached £700 million (approximately $890 million) in the same period.The strong sales of the RSV vaccine reflect the market's enthusiasm and its robust performance, indicating that there is still a vast amount of unmet market demand in the blue ocean market, which calls for companies to fill the gap by launching new products.

In the future, the RSV vaccine market will still be led by international giants, with Chinese manufacturers following. Companies with marketed products will seize the first-mover advantage, gaining an edge in vaccine research, development, and promotion.According to GSK's announcement, the pivotal Phase III trial of its RSV vaccine showed positive results. In the trial, the vaccine demonstrated 82.6% efficacy against RSV-LRTD in adults aged 60 years and above, with significant statistical and clinical importance, meeting the primary endpoint of the clinical trial. This indicates that the vaccine has strong protective efficacy and safety. With its excellent clinical performance, the vaccine has been approved for production and market launch. Currently, there are only two vaccines available globally, and companies with marketed products have a first-mover advantage, allowing them to capture market share ahead of competitors.

At the same time, the progress of products under research by Chinese pharmaceutical companies is accelerating. Once approved and launched in the future, they will occupy market share and achieve import substitution.China has not yet approved any RSV vaccine products for marketing, but the development of domestically produced RSV vaccines is accelerating. Advaccine is leading in clinical progress, with its product ADV110 showing good safety and tolerability, having advanced to Phase II clinical trials. In addition, several listed vaccine companies such as Clover Biopharmaceuticals, Walvax Biotechnology, CSPC Pharmaceutical Group, Aim Vaccine, and Zhifei Biological Products are also laying out pipelines for RSV vaccines, accelerating the R&D of RSV vaccine products. In the future, with the approval and market launch of domestically produced RSV vaccines, the market landscape dominated by foreign manufacturers will change, and domestic products are expected to achieve import substitution based on their own advantages.